Asher Mullard
Impact in
- Pharmaceutical Science top 1%
- Computational Theory and Mathematics top 0.5%
- Computational Drug Discovery Methods
Papers in
-
- Pharmaceutical Economics and Policy 106
- Oncology 68
- Cancer Immunotherapy and Biomarkers 35
- Co-authors
- Alaa El-Husseini (3 shared papers)Rujun Kang (3 shared papers)Anat Yanai (2 shared papers)Kun Huang (2 shared papers)Michael R. Hayden (2 shared papers)Roshni Rebecca Singaraja (2 shared papers)Pamela Arstikaitis (2 shared papers)Martina Metzler (1 shared paper)
- Journals
- Nature Reviews Drug Discovery (481 papers)Nature (18 papers)The Lancet (15 papers)Nature Reviews Molecular Cell Biology (14 papers)Nature Biotechnology (11 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Asher Mullard
529 papers receiving 8.4k citations
Asher Mullard's Hit Papers
Peers
Comparison fields: 5 of 166
- Pharmaceutical Science 353
- Computational Theory and Mathematics 818
- Oncology 997
- Molecular Biology 2.1k
- Immunology 537
Countries citing papers authored by Asher Mullard
This map shows the geographic impact of Asher Mullard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Asher Mullard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Asher Mullard more than expected).
Fields of papers citing papers by Asher Mullard
This network shows the impact of papers produced by Asher Mullard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Asher Mullard. The network helps show where Asher Mullard may publish in the future.
Co-authors
The 25 scholars most cited alongside Asher Mullard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 559 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 268 | |
| 2 | 2006 | 267 | |
| 3 | 2013 | 246 | |
| 4 | 2016 | 232 | |
| 5 | 2012 | 211 | |
| 6 | 2020 | 184 | |
| 7 | 2017 | 166 | |
| 8 | 2014 | 161 | |
| 9 | 2021 | 157 | |
| 10 | 2012 | 139 | |
| 11 | 2018 | 119 | |
| 12 | 2016 | 117 | |
| 13 | 2013 | 115 | |
| 14 | 2021 | 104 | |
| 15 | 2017 | 103 | |
| 16 | 2022 | 103 | |
| 17 | 2021 | 102 | |
| 18 | 2015 | 100 | |
| 19 | 2023 FDA approvals Hit paper breakdown → | 2024 | 100 |
| 20 | 2020 | 98 |
About Asher Mullard
Asher Mullard is a scholar working on Economics and Econometrics, Oncology, Physiology, Molecular Biology and Infectious Diseases, having authored 559 papers that have together received 8.8k indexed citations. Recurring topics across this work include Pharmaceutical Economics and Policy (106 papers), Cancer Immunotherapy and Biomarkers (35 papers), Computational Drug Discovery Methods (25 papers), Monoclonal and Polyclonal Antibodies Research (24 papers), Alzheimer's disease research and treatments (24 papers), SARS-CoV-2 and COVID-19 Research (22 papers), Pharmaceutical industry and healthcare (20 papers) and Protein Degradation and Inhibitors (19 papers). The work is most often cited by research in Pharmaceutical Science (353 citations), Computational Theory and Mathematics (818 citations), Oncology (997 citations), Molecular Biology (2.1k citations) and Immunology (537 citations). Asher Mullard has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Alaa El-Husseini, Rujun Kang, Anat Yanai, Kun Huang, Michael R. Hayden, Roshni Rebecca Singaraja, Pamela Arstikaitis, Martina Metzler, Brendan Haigh and Claire‐Anne Gutekunst. Their work appears in journals such as Nature Reviews Drug Discovery, Nature, The Lancet, Nature Reviews Molecular Cell Biology and Nature Biotechnology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.